Syncom Formulations Reports Strong Quarterly Growth Amid Long-Term Challenges
Syncom Formulations (India) has recently adjusted its evaluation, reflecting a strong financial performance for the quarter ending December 2024, with a significant increase in net sales. However, long-term growth faces challenges, as historical data shows substantial declines in net sales and operating profit over the past five years.
Syncom Formulations (India), a small-cap player in the Pharmaceuticals & Drugs sector, has recently undergone an evaluation adjustment that reflects its current market standing. The company reported very positive financial performance for the quarter ending December 2024, showcasing a notable growth in net sales of 24.65%. This growth is underscored by the highest quarterly net sales recorded at Rs 127.53 crore, alongside impressive figures for PBDIT and PBT.However, the long-term growth trajectory presents challenges, with net sales declining at an annual rate of -80.90% and operating profit at -73.21% over the past five years. The stock is currently positioned in a mildly bearish range, with technical indicators suggesting a shift from a sideways trend.
Despite a return of 2.52% over the past year and a significant profit increase of 48.3%, the company's valuation appears expensive, indicated by a Price to Book Value ratio of 4.8. Additionally, domestic mutual funds hold no stake in the company, which may reflect caution regarding its pricing or business fundamentals.
For more insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
